Core Concepts
Secondary cancers post CAR T therapy are a concern, with T-cell malignancies being a significant issue.
Stats
Secondary cancers were flagged in 4.3% of all adverse event reports among patients who received CAR T therapy.
T-cell malignancies comprised only 0.15% of the total reports and 3.54% of all second primary malignancies.
536 adverse events (4.3%) were second primary malignancies post CAR T therapy.
Axicabtagene ciloleucel and tisagenlecleucel accounted for most of the second primary malignancies reports.
19 cases of T-cell malignancies were identified, representing only 0.15% of all unique adverse events and 3.54% of all second primary malignancies.
Among the reported 536 second primary malignancies, the most frequent cancers were leukemias (62%), followed by skin neoplasms (10.1%).
Quotes
"We will continue to monitor the data released by the FDA to learn more about CAR T-associated risks." - Magdi Elsallab